Almotriptan - CAS 154323-57-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Almotriptan
Catalog Number:
154323-57-6
Synonyms:
N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine Almotriptan 154323-57-6 Almogran Almotrintan LAS-31416 UNII-1O4XL5SN61 Almotriptan (USAN) CHEBI:520985 Spectrum_001884
CAS Number:
154323-57-6
Description:
Almotriptan, also called as Almogran, is a agonist with high and specific affinity for 5-HT1B/1D receptors. developed by Almirall Prodesfarma for the acute treatment of migraine with or without aura. Besides, it acts very selectively at human cranial vess
Molecular Weight:
335.46
Molecular Formula:
C17H25N3O2S
Quantity:
Grams-Kilos
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
InChI:
1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
InChIKey:
WKEMJKQOLOHJLZ-UHFFFAOYSA-N
Targets:
5-HT Receptor
Chemical Structure
CAS 154323-57-6 Almotriptan

Related 5-HT Receptor Products


AVN-211
(CAS: 1173103-84-8)

This active molecular is a Selective 5-HT6 Receptor antagonist, for the treatment of Alzheimer's Disease under development by by Avineuro Pharmaceuticals. AVN-2...

Revexepride
(CAS: 219984-49-3)

Revexepride, also referred as SSP-002358, is a very selective and potent 5-HT4 receptor agonist and a novel prokinetic that stimulates gastrointestinal motility...

CAS 121679-13-8 Naratriptan

Naratriptan
(CAS: 121679-13-8)

Naratriptan, a 5-HT1B/1D receptor agonist, could be used in the treatment of migraine.

CAS 123040-16-4 Azasetron hydrochloride

Azasetron hydrochloride
(CAS: 123040-16-4)

Azasetron HCl is a selective 5-HT3 receptor antagonist with IC50 of 0.33 nM used in the management of nausea and vomiting induced by cancer chemotherapy.

CAS 222551-17-9 Adoprazine

Adoprazine
(CAS: 222551-17-9)

Adoprazine, also known as SLV 313, with potential antipsychotic property, is a agonist of cloned h5-HT(1A) receptors (pEC(50)=9.0) and a full antagonist of hD(2...

CAS 145202-66-0 Rizatriptan Benzoate

Rizatriptan Benzoate
(CAS: 145202-66-0)

Rizatriptan Benzoate is a 5-HT1 agonist triptan drug for the treatment of migraine headaches.

LY 302148
(CAS: 182564-47-2)

LY 302148 is a 5-HT1F receptor agonist with potential for migraine therapeutics.

CAS 179756-85-5 Eptapirone

Eptapirone
(CAS: 179756-85-5)

Eptapirone, a triazine derivative, has been found to be a 5-HT1A receptor agonist and was once studied as an antidepressant agent. pKi: 8.33.

CAS 87760-53-0 Tandospirone

Tandospirone
(CAS: 87760-53-0)

Tandospironeis a potent and selective 5-HT1A receptor partial agonist with Ki of 27 nM. It significantly reduces haloperidol-induced bradykinesia in a dose depe...

Asenapine hydrochloride
(CAS: 1412458-61-7)

Asenapine hydrochloride, also called Org 5222 and HSDB 8061, shows high affinity for numerous receptors including 5-HT receptor and adrenergic receptor. (pKi: 5...

CAS 30123-17-2 Tianeptine sodium

Tianeptine sodium
(CAS: 30123-17-2)

Tianeptine sodium is a selective serotonin reuptake enhancer (SSRE), used for treating major depressive episodes.

Elzasonan citrate
(CAS: 361343-20-6)

Elzasonan citrate is a selective 5-hydroxytryptamine 1B receptor antagonist for treat patients with major depressive disorder and obsessive compulsive disorder.

Naratriptan D3 Hydrochloride
(CAS: 1190021-64-7)

The hydrochloride salt form of isotope labelled Naratriptan which is a selective 5-HT1 receptor agonist and could be used against migraine headaches.

CAS 1089115-06-9 Aripiprazole-D8

Aripiprazole-D8
(CAS: 1089115-06-9)

An isotopic labeled form of aripiprazole, a dihydroquinolinone derivative, is an antagonist of Dopamine-2 receptor and a partial agonist of 5-HT1A receptor whic...

(R)-6-Hydroxybuspirone hydrochloride
(CAS: 477930-30-6)

(R)-6-Hydroxybuspirone is a major active metabolite of Buspirone. (R)-Enantiomer showed higher affinity and selectivity for the 5HT1A receptor compared to the ...

CAS 329218-11-3 Quetiapine sulfoxide dihydrochloride

Quetiapine sulfoxide dihydrochloride
(CAS: 329218-11-3)

Quetiapine sulfoxide dihydrochloride, a metabolite of Quetiapine, has antipsychotic effect.

CAS 17321-77-6 Clomipramine HCl

Clomipramine HCl
(CAS: 17321-77-6)

Clomipramine HCl is a hydrochloride salt of clomipramine which is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) bl...

CAS 109889-09-0 Granisetron

Granisetron
(CAS: 109889-09-0)

Granisetron is an antagonist of serptpmom 5-HT3 receptor and could be used to relieve the nausea and vomiting symptom after receving chemotherapy by decreasing ...

CAS 706779-91-1 Pimavanserin

Pimavanserin
(CAS: 706779-91-1)

Pimavanserin is a potent and selective 5-HT2A receptor inverse agonist used in the treatment of Parkinson’s disease psychosis.

Agomelatine L(+)-Tartaric acid
(CAS: 824393-18-2)

Agomelatine L(+)-Tartaric acid is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. It is used as an ant...

Reference Reading


1.The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.
Marmura MJ1, Silberstein SD, Schwedt TJ. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499.
The study aims to provide an updated assessment of the evidence for individual pharmacological therapies for acute migraine treatment. Pharmacological therapy is frequently required for acutely treating migraine attacks. The American Academy of Neurology Guidelines published in 2000 summarized the available evidence relating to the efficacy of acute migraine medications. This review, conducted by the members of the Guidelines Section of the American Headache Society, is an updated assessment of evidence for the migraine acute medications. A standardized literature search was performed to identify articles related to acute migraine treatment that were published between 1998 and 2013. The American Academy of Neurology Guidelines Development procedures were followed. Two authors reviewed each abstract resulting from the search and determined whether the full manuscript qualified for review. Two reviewers studied each qualifying full manuscript for its level of evidence.
2.Efficacy of frovatriptan as compared to other triptans in migraine with aura.
Evers S1, Savi L, Omboni S, Lisotto C, Zanchin G, Pinessi L. J Headache Pain. 2015;16:514. doi: 10.1186/s10194-015-0514-8. Epub 2015 Apr 1.
BACKGROUND: The treatment of migraine attacks with aura by triptans is difficult since triptans most probably are not efficacious when taken during the aura phase. Moreover, there are insufficient data from randomised studies whether triptans are efficacious in migraine attacks with aura when taken during the headache phase. In this metaanalysis, we aimed to compare the efficacy of frovatriptan versus rizatriptan, zolmitriptan, and almotriptan.
3.Gellan gum-based mucoadhesive microspheres of almotriptan for nasal administration: Formulation optimization using factorial design, characterization, and in vitro evaluation.
Abbas Z1, Marihal S1. J Pharm Bioallied Sci. 2014 Oct;6(4):267-77. doi: 10.4103/0975-7406.142959.
BACKGROUND: Almotriptan malate (ALM), indicated for the treatment of migraine in adults is not a drug candidate feasible to be administered through the oral route during the attack due to its associated symptoms such as nausea and vomiting. This obviates an alternative dosage form and nasal drug delivery is a good substitute to oral and parenteral administration.
4.The therapeutic armamentarium in migraine is quite elderly.
Martelletti P1. Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):175-7. doi: 10.1517/17425255.2015.982089. Epub 2014 Dec 1.
Global Burden of Disease 2010 study considers migraine as one of the most important noncommunicable diseases in the world, classifying it third in terms of global prevalence (14.70%): it sums up the 54.19% of all the years of life lived with disabilities caused by the rest of all neurological disorders. This Editorial provides an historical excursus of old and new-entry molecules in migraine therapeutic area. Drugs for acute treatment such as triptans date back to the early 1990s with the appearance of sumatriptan and the following six triptans in the years immediately after (zolmitriptan, rizatriptan, naratriptan, eletriptan, almotriptan, frovatriptan). Prophylaxis drugs, dedicated to patients with medium/high frequency of crises, show as last entries topiramate and botulinum toxin type A. The use of this preventative group, with its intrinsic limits, is mandatory to reduce the risk of migraine chronification, a highly harmful clinical phenomenon that produces as its natural consequence the medication overuse headache.